Literature DB >> 2192056

Drug-drug interactions with antirheumatic agents: review of selected clinically important interactions.

C F Stewart1, W E Evans.   

Abstract

Drug therapy for rheumatoid arthritis (RA) often requires the use of more than one drug, thus drug-drug interactions are very likely in this patient population. We discuss the pharmacokinetic and pharmacodynamic mechanisms involved in drug-drug interactions. Our review focuses on selected examples involving drugs used to treat RA and other antirheumatic drugs [e.g., methotrexate and nonsteroidal antiinflammatory drugs (NSAID)] or with other therapeutic classes of drugs (e.g., NSAID and warfarin). Studies and case reports of drug-drug interactions with antirheumatic drugs are critically evaluated and the potential clinical implications are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2192056

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  10 in total

Review 1.  Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.

Authors:  Christiane M Rordorf; Les Choi; Paul Marshall; James B Mangold
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 3.  Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Authors:  M Schwab; U Klotz
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases.

Authors:  Jirí Grim; Jaroslav Chládek; Jirina Martínková
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis.

Authors:  Jaroslav Chládek; Jiøí Grim; Jiøina Martínková; Marie Simková; Jaroslava Vanìèková; Vìra Koudelková; Marie Noièková
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

Review 6.  Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs). Recognition, management and avoidance.

Authors:  A G Johnson; P Seideman; R O Day
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

7.  Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis.

Authors:  C Lebbe; C Beyeler; N J Gerber; J Reichen
Journal:  Ann Rheum Dis       Date:  1994-07       Impact factor: 19.103

Review 8.  A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis.

Authors:  A A Kalla; A F Tooke; E Bhettay; O L Meyers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 9.  Methotrexate in rheumatoid arthritis. An update.

Authors:  B Bannwarth; L Labat; Y Moride; T Schaeverbeke
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 10.  Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  J R Brouwers; P A de Smet
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.